← brief for 2026-10-09 · Slowing decline

Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease.

Article C Peer reviewed Observational

Key takeaways

This study looked at 126 people with diabetes and kidney disease who took two new drugs together. It checked if the combo helped control blood sugar and kidney function. It shows a link to better results, but it is not a proof of cause. Doctors are watching for side effects in this group.

Who did this work

Gong C · Luo Q · Li Q

Source

Article · PubMed, the drug frontier · 2026 Oct 9
https://pubmed.ncbi.nlm.nih.gov/42854065/